How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type 2 diabetes and established cardiovascular (CV) disease, empagliflozin given in addition to standard of care reduced the risk of CV death by 38% versus placebo (hazard ratio [HR] 0.62 [95% CI 0.49, 0.77]). This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to CV death risk reduction with empagliflozin. RESEARCH DESIGN AND METHODS: Effects of potential mediators, identified post hoc, on the HR for CV death with empagliflozin versus placebo were analyzed by Cox regression models, with treatment group adjusted for the baseline value of the variable and its change from baseline or updated mean (i.e., considering all prior values), each as a time-dependent covariate. HRs were compared with a model without adjustment for covariates. Multivariable analyses also were performed. RESULTS: Changes in hematocrit and hemoglobin mediated 51.8% and 48.9%, respectively, of the effect of empagliflozin versus placebo on the risk of CV death on the basis of changes from baseline, with similar results in analyses on the basis of updated means. Smaller mediation effects (maximum 29.3%) were observed for uric acid, fasting plasma glucose, and HbA1c. In multivariable models, which incorporated effects of empagliflozin on hematocrit, fasting glucose, uric acid, and urine albumin:creatinine ratio, the combined changes from baseline provided 85.2% mediation, whereas updated mean analyses provided 94.6% mediation of the effect of empagliflozin on CV death. CONCLUSIONS: In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in markers of plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both have been identified as important determinants of the heart failure benefits of these drugs in trials of patients with type 2 diabetes.”
From Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (2021) · cites this paper as [32]
In the citing paper
“Those that appear particularly plausible include effects on volume status, natriuresis, expansion of red blood cell mass, and myocardial energetics (34,36,59,62,64).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
In the citing paper
“Thus, the mechanisms by which SGLT2 inhibitors reduce the risk for HF are not attributable to improved glycemic control (59).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
Citations
Cites
Baron, R. M., & Kenny, D. A. (1986) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.51.6.1173 · Cited by 91,532 · cited 2×
“A traditional mediation analysis as originally proposed by Baron and Kenny (12) was used, taking the time-dynamic evolvement of both the potential mediators and the outcome CV death into account.”
Method(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Introduction to Statistical Mediation Analysis
MacKinnon, D. P. (2012) · doi:10.4324/9780203809556 · Cited by 5,618
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationUric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329 · cited 1×
“Moreover, only variablesmeasured during the trial could be examined, and in addition to the potential mediators we investigated, other variables such as reductions in glomerular hyperfiltration (35), reductions in arterial stiffness and vascular resistance (36), direct cardiac effects through reductions in myocardial…”
BackgroundSelf-citationLow Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155 · cited 1×
“Therefore, many participants in this trial likely had unrecognized left ventricular dysfunction, particularly diastolic dysfunction, which may eventually lead to clinical heart failure with preserved ejection fraction (25).”
Background
Research works printed but not linked: 2
- Fitchett, Further exploration of the cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease in EMPA-REG OUTCOME, J Am Coll Cardiol
- Boehringer Ingelheim. Empagliflozin (Jardiance®) to be studied in chronic kidney disease. 2017. Available from https://www.boehringer-ingelheim.com/press-release/empagliflozin-be-studied-chronic-kidney-disease. Accessed 6 September 2017
Cited by
Items 201–300 of 762
Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Flores, E., Santos‐Gallego, C. G., Mejia, N. M. D., & Badimón, J. J. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6786-x · Cited by 46
“The osmotic diuresis and the subsequent reduction in plasma volume have been considered as a more plausible explanation using mathematical models [52] but the diuretic hypothesis could be challenged when results of EMPAREG are compared to those of other classic diuretics that did not show CV benefits (in fact, no diur…”
ResultSawada, T., Uzu, K., Hashimoto, N., Onishi, T., Takaya, T., Shimane, A., Taniguchi, Y., Yasaka, Y., Ohara, T., & Kawai, H. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.50807 · Cited by 44
Cherney, D. Z. I., Heerspink, H. J. L., Frederich, R., Maldonado, M., Liu, J., Pong, A., Xu, Z. J., Patel, S., Hickman, A., Mancuso, J. P., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05133-4 · Cited by 43
Ceriello, A., Ofstad, A. P., Zwiener, I., Kaspers, S., George, J. T., & Nicolucci, A. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01147-9 · Cited by 45
Self-citationPellicori, P., FITCHETT, D. H., Kosiborod, M., Ofstad, A. P., SEMAN, L. J., Zinman, B., Zwiener, I., Wanner, C., George, J. T., Inzucchi, S. E., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2220 · Cited by 44
Self-citationPiepoli, M. F., Adamo, M., Barison, A., Bestetti, R. B., Biegus, J., Böhm, M., Butler, J., Carapetis, J. R., Ceconi, C., Chioncel, O. D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab147 · Cited by 49
Effects of SGLT2 inhibition on lipid transport in adipose tissue in type 2 diabetes
Lauritsen, K. M., Voigt, J. H., Pedersen, S. B., Hansen, T. K., Møller, N., Jessen, N., Gormsen, L. C., & Søndergaard, E. (2022) · Endocrine Connections · doi:10.1530/ec-21-0558 · Cited by 45
Liakos, C. I., Papadopoulos, D. P., Sanidas, E. A., Markou, M. I., Hatziagelaki, E. E., Grassos, C. A., Velliou, M. L., & Barbetseas, J. D. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00423-z · Cited by 43
Segar, M. W., Kolkailah, A. A., Frederich, R. C., Pong, A., Cannon, C. P., Cosentino, F., Dagogo-Jack, S. E., McGuire, D. K., Pratley, R. E., Liu, C., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14769 · Cited by 44
“Previous mediation analyses from the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPAREG OUTCOME) trial reported changes in haemoglobin and haematocrit as the strongest mediators of reduced cardiac death risk with empagliflozin when compared with placebo.(19) Subsequent media…”
MethodResultInfluentialMechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Liu, B., Wang, Y., Zhang, Y., & Yan, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190828161409 · Cited by 45
Packer, M. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107647 · Cited by 43
Nevola, R., Alfano, M., Pafundi, P. C., Brin, C., Gragnano, F., Calabrò, P., Adinolfi, L. E., Rinaldi, L., Sasso, F. C., & Caturano, A. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2303106 · Cited by 49
Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines
Tsutsui, H. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108185 · Cited by 47
Hupfeld, C., & Mudaliar, S. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13740 · Cited by 41
“plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo.(48) A”
BackgroundBjornstad, P., Greasley, P. J., Wheeler, D. C., Chertow, G. M., Langkilde, A. M., Heerspink, H. J. L., & van Raalte, D. H. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.07.003 · Cited by 42
Rastogi, A., & Januzzi, J. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082824 · Cited by 42
“Data from EMPA-REG OUTCOME [14,63], DECLARE-TIMI 58 [18,69], DELIVER [25,30], VERTIS-CV [19,62], and CREDENCE [28,64] suggest that the early eGFR decrease should not be cause for concern unless there are signs and symptoms of volume depletion (orthostatic hypotension, blood pressure [BP] <120/70 mmHg), specifically in…”
BackgroundMethodInfluentialVallon, V. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae060 · Cited by 46
Wang, C., Li, Y., Qian, X.-Q., Zhao, H., Wang, D., Zuo, G.-X., & Kuan, W. (2022) · Figshare · doi:10.6084/m9.figshare.20525647 · Cited by 41
Effects of sodium glucose co-transporter 2 inhibitors on the kidney
de Albuquerque Rocha, N., Neeland, I. J., McCullough, P. A., Toto, R. D., & McGuire, D. K. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118783756 · Cited by 41
Lamos, E. M., Hedrington, M. S., & Davis, S. N. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1626823 · Cited by 46
“to 50% of the favorable effect of empagliflozin on cardiovascular mortality compared to placebo [106], possibly reflecting”
BackgroundAroda, V. R., & Eckel, R. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14830 · Cited by 43
Pan, J., Liu, M., Huang, J., Chen, L., & Xu, Y. (2024) · Clinical Cardiology · doi:10.1002/clc.24228 · Cited by 46
“41,42 45 Renin ‐ angiotensin system inhibitors have been verified through meta ‐ analysis to raise the risk of anemia.”
BackgroundSGLT2 inhibition and heart failure—current concepts
da Silva, J. C., Durães, A. R., Abreu, M., Rocha, N. A., & Roever, L. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9703-2 · Cited by 44
Cardiac Biomarkers and Risk of Atrial Fibrillation in Chronic Kidney Disease: The CRIC Study
Lamprea-Montealegre, J. A., Zelnick, L. R., Shlipak, M. G., Floyd, J. S., Anderson, A. H., He, J., Christenson, R. H., Seliger, S. L., Soliman, E. Z., Deo, R., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012200 · Cited by 40
“Specifically, sodium-glucose-cotransporter-2 inhibitors have direct hemodynamic effects because of significant reductions in plasma volume reducing intracardiac filling pressures and myocardial injury.(43,44) Furthermore, our observation may help identify patients at highest risk for cardiovascular disease who would p…”
BackgroundIbrahim, A., Ghaleb, R., Mansour, H. M., Hanafy, A., Mahmoud, N. M., Elsharef, M. A., Salama, M. K., Elsaughier, S. M., Abdel-Wahid, L., Mohamed, M. E., et al. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.602251 · Cited by 45
Ferreira, J. P., Fitchett, D., Ofstad, A. P., Kraus, B. J., Wanner, C., Zwiener, I., Zinman, B., Lauer, S., George, J. T., Rossignol, P., et al. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa073 · Cited by 39
“…in markers of plasma volume as the most important mediators of the reduction of CV death in empagliflozin-treated patients and showed that SBP and DBP had only negligible mediating effects, 16 it is well established that BP control is important to improve outcomes in patients with T2D and CVD.”
BackgroundMethodSelf-citationFerreira, J. P., Sharma, A., Mehta, C. R., Bakris, G. L., Rossignol, P., White, W. B., & Zannad, F. M. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01729-3 · Cited by 42
Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats
Kuno, A., Kimura, Y., Mizuno, M., Oshima, H., Sato, T., Moniwa, N., Tanaka, M., Yano, T., Tanno, M., Miki, T., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-64380-y · Cited by 38
Lawler, P. R., Liu, H., Frankfurter, C., Lovblom, L. E., Lytvyn, Y., Burger, D. E., Burns, K. D., Brinc, D., & Cherney, D. Z. I. (2021) · Diabetes Care · doi:10.2337/dc20-2265 · Cited by 38
Tanaka, A., Shimabukuro, M., Teragawa, H., Okada, Y., Takamura, T., Taguchi, I., Toyoda, S., Tomiyama, H., Ueda, S., Higashi, Y., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01295-6 · Cited by 37
“Interestingly, two recent mediation analyses of data obtained from CVOTs (the EMPA-REG OUTCOME trial and the CANVAS program) suggested that changes in markers of erythropoiesis and volume status were the most important mediators of the decreases in the risk of HHF and cardiovascular death [12, 13].”
MethodKoufakis, T., Mustafa, O. G., Ajjan, R., García–Moll, X., Zebekakis, P. E., Dimitriadis, G., & Kotsa, K. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13107 · Cited by 36
Kuriyama, S. (2019) · Kidney & Blood Pressure Research · doi:10.1159/000501081 · Cited by 37
Bayés‐Genís, A., Bisbal, F., Núñez, J. E., Santas, E., Lupón, J., Rossignol, P., & Paulus, W. J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041110 · Cited by 39
“Interestingly, the diuretic effect of these compounds (as assessed by increases in hematocrit) has been demonstrated and found to mediate a major component of the beneficial effect demonstrated in the EMPAgliflozin, cardiovascular OUTCOMES and mortality in type 2 diabetes -EMPA-REG OUTCOME- trial [75].”
BackgroundXiang, B., Zhao, X.-Y., & Zhou, X. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01266-x · Cited by 37
“This was later confirmed in several analyses of the EMPA-REG OUTCOME trial [13, 14].”
BackgroundResultRecent advances in pharmacological treatment of heart failure
Iacoviello, M., Palazzuoli, A., & Gronda, E. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13624 · Cited by 39
Xie, L., & Wenfang, X. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120543 · Cited by 36
Lim, J., Choi, Y.-J., Kim, B. S., Rhee, T., Lee, H.-J., Han, K. D., Park, J., Na, J. O., Kim, Y.-J., Lee, H., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01911-7 · Cited by 34
Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction
Doehner, W., Anker, S. D., Butler, J., Zannad, F. M., Filippatos, G., Coats, A. J. S., Ferreira, J. P., Henrichmoeller, I., Brueckmann, M., Schueler, E., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.08.020 · Cited by 35
Deschaine, B., Verma, S., & Rayatzadeh, H. (2022) · Cardiac failure review · doi:10.15420/cfr.2022.11 · Cited by 37
Scholtes, R. A., van Baar, M. J. B., Lytvyn, Y., Bjornstad, P., Nieuwdorp, M., Cherney, D. Z. I., & van Raalte, D. H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13692 · Cited by 35
“Notably, the increase in hematocrit (Ht) was the strongest predictor of CV benefit in EMPA-REG OUTCOME.(65) These”
BackgroundInfluentialPreventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors
Vaduganathan, M., & Januzzi, J. L. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.026 · Cited by 34
Reifsnider, O. S., Kansal, A., Pimple, P. M., Ribero, V. A., Brand, S. B., & Shetty, S. S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14268 · Cited by 34
“Methods: An individual simulation model predicted lifetime diabetes-related complica- tions, using UKPDS-OM2 equations in patients without CVD, and EMPA-REGOUTCOME equations in patients with CVD. Additional US-based sources informed inputs for popula- tion characteristics, adverse events, non-CV death, treatment escal…”
MethodInfluentialGirardi, A. C. C., Polidoro, J. Z., Castro, P. C., Pio-Abreu, A., Noronha, I. L., & Drager, L. F. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00143.2024 · Cited by 32
Lan, N. S. R., Yeap, B. B., Fegan, P. G., Green, G., Rankin, J. M., & Dwivedi, G. (2020) · International journal of cardiac imaging · doi:10.1007/s10554-020-02034-w · Cited by 32
Clegg, L. E., Heerspink, H. J. L., Penland, R. C., Tang, W., Boulton, D. W., Bachina, S., Fox, R. D., Fenici, P., Thuresson, M., Mentz, R. J., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1871 · Cited by 33
Deerochanawong, C., Chan, S. P., Matawaran, B. J., Sheu, W. H., Chan, J. C. N., Man, N. H., Suastika, K., Khoo, C. M., Yoon, K., Luk, A. O. Y., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13819 · Cited by 31
“9%, respectively, of the effect of empagliflozin vs placebo on the risk of CV death).(114) In Asian patients”
BackgroundHare, G. M. T., Zhang, Y., Chin, K., Thai, K., Jacobs, E., Cazorla‐Bak, M. P., Nghiem, L., Wilson, D. F., Vinogradov, S. A., Connelly, K. A., et al. (2021) · Physiological Reports · doi:10.14814/phy2.14890 · Cited by 33
Zhou, H., Peng, W., Li, F., Wang, Y., Wang, B., Ding, Y., Lin, Q., Zhao, Y., Pan, G., & Wang, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.875327 · Cited by 34
“Additional mechanisms of SGLT2 inhibitors that might be beneficial include increased hematocrit level (86), inhibition of the Na/H-exchanger (87), prevention of adverse cardiac remodeling (88), prevention of ischemia/reperfusion injury (89), reduced serum uric acid level (90), reduced glomerular hyperfiltration and al…”
BackgroundFerreira, J. P., Vasques‐Nóvoa, F., Saraiva, F. A., Oliveira, A., Almeida, J., Batista, A. B., Barbosa, A., Ferreira, A. F., Costa, C., Diaz, S. O., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.05.033 · Cited by 30
Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes
van Bommel, E. J. M., Smits, M. M., Ruiter, D., Muskiet, M. H. A., Kramer, M. H. H., Nieuwdorp, M., Touw, D. J., Heerspink, H. J. L., Joles, J. A., & van Raalte, D. H. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002480 · Cited by 30
“The observed reduction in plasma volume (as reflected by increased hematocrit) is thought to be a main determinant of the beneficial effects of SGLT2 inhibitors on major adverse cardiovascular events, in particular heart failure, and mortality in patients with atherosclerotic disease [2].”
BackgroundMechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis
Gronda, E., Lopaschuk, G. D., Arduini, A., Santoro, A., Benincasa, G., Palazzuoli, A., Gabrielli, D., & Napoli, C. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2021-0399 · Cited by 31
The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1
Oe, Y., & Vallon, V. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2020032 · Cited by 34
“The increase in erythropoietin and the diuretic effect of SGLT2 inhibitors promote a small rise increase in hematocrit and hemoglobin [101], which improves oxygen delivery to the kidney and other organs.”
BackgroundNew insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling
Chen, Y., & Peng, D. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110072 · Cited by 30
Irace, C., Cutruzzolà, A., Parise, M., Fiorentino, R., Frazzetto, M., Gnasso, C., Casciaro, F., & Gnasso, A. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119883540 · Cited by 30
Sarzani, R., Giulietti, F., Pentima, C. D., & Spannella, F. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.05.030 · Cited by 31
Matsumura, K., & Sugiura, T. (2019) · Cardiovascular Ultrasound · doi:10.1186/s12947-019-0177-8 · Cited by 30
SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?
Santos‐Ferreira, D., Gonçalves-Teixeira, P., & Fontes‐Carvalho, R. (2019) · Cardiology · doi:10.1159/000504694 · Cited by 33
Albiero, M., Tedesco, S., Amendolagine, F. I., D’Anna, M., Migliozzi, L., Zuccolotto, G., Rosato, A., Cappellari, R., Avogaro, A., & Fadini, G. P. (2021) · Diabetes · doi:10.2337/db20-1045 · Cited by 29
Jacob, S., Krentz, A. J., Deanfield, J. E., & Rydén, L. (2021) · Drugs · doi:10.1007/s40265-021-01554-6 · Cited by 34
Halvorsen, Y. C., Lock, J. P., Frías, J. P., Tinahones, F. J., Dahl, D. B., Conery, A. L., & Freeman, M. W. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14875 · Cited by 31
Renoprotective Effects of SGLT2 Inhibitors
Vallon, V. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.005 · Cited by 33
Belli, M., Barone, L., Bellia, A., Sergi, D., Lecis, D., Prandi, F. R., Milite, M., Galluccio, C., Muscoli, S., Romeo, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314598 · Cited by 29
Takasu, T., & Takakura, S. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.051 · Cited by 29
Sattar, N. A. (2019) · BMC Medicine · doi:10.1186/s12916-019-1281-1 · Cited by 31
“largely independent of their glycaemic effects has helped refocus the field on novel risk pathways for these benefits, as well on providing new understanding of the complication risks in diabetes [14].”
BackgroundKyriakos, G., Quiles-Sánchez, L. V., Garmpi, A., Farmaki, P., Kyre, K., Savvanis, S., Antoniou, V., & Memi, E. (2019) · Current Cardiology Reviews · doi:10.2174/1573403x15666190730094215 · Cited by 28
“However, similar results were obtained across different countries [15-18].”
BackgroundResultTheofilis, P., Oikonomou, E. K., Tsioufis, K. P., & Tousoulis, D. (2023) · Life · doi:10.3390/life13020497 · Cited by 34
SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes
Mukhopadhyay, P., Sanyal, D., Chatterjee, P., Pandit, K., & Ghosh, S. K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad113 · Cited by 28
Verma, S., Mudaliar, S. R., & Greasley, P. J. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02652-5 · Cited by 30
Lewis, M., Burrack, N., Heymann, A. D., Grossman, A., Neuman, T., & Abuhasira, R. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.17086 · Cited by 28
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
Cavaiola, T. S., & Pettus, J. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s154602 · Cited by 27
“However, further questions may now arise following a recent exploratory investigation into potential mediators of the reduction in risk of CV death with empagliflozin versus placebo during the EMPA-REG OUTCOME trial, in which it was reported that changes in some traditional CV risk factors (including obesity, BP, lipi…”
Januzzi, J. L., Ferreira, J. P., Böhm, M., Kaul, S., Wanner, C., Brueckmann, M., Petrie, M. C., Ofstad, A. P., Zeller, C., George, J. T., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1419 · Cited by 28
Self-citationTochiya, M., Makino, H., Tamanaha, T., Matsuo, M., Hishida, A., Koezuka, R., Ohata, Y., Tomita, T., Son, C., Miyamoto, Y., et al. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13122 · Cited by 27
Marques, P. S., Matias, P., Packer, M., Vieira, J. T., Vasques‐Nóvoa, F., Sharma, A., Mavrakanas, T. A., Friões, F., & Ferreira, J. P. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2992 · Cited by 27
Zhao, D., Liu, H., & Dong, P. (2018) · Journal of Human Hypertension · doi:10.1038/s41371-018-0134-2 · Cited by 31
CaMKII and GLUT1 in heart failure and the role of gliflozins
Trum, M., Wagner, S., Maier, L. S., & Mustroph, J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165729 · Cited by 30
Verma, S., Sharma, A., Zinman, B., Ofstad, A. P., FITCHETT, D. H., Brueckmann, M., Wanner, C., Zwiener, I., George, J. T., Inzucchi, S. E., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14015 · Cited by 28
“A mediation analysis exploring the potential underlying mechanisms of empagliflozin's reduction in CV death found that changes in haematocrit and haemoglobin (suggesting haemoconcentration from reduction in plasma volume) appeared to be the most important mediators.(24) Recent analyses from the EMPA-HEART CardioLink-6…”
ResultSelf-citationPacker, M. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa344 · Cited by 27
“Changes in haemoglobin and serum urate are the most powerful predictors of the reduction in serious heart failure events with SGLT2 inhibitors in large-scale trials.(8,9) Furthermore, activation of SIRT1 may contribute to the ability of SGLT2 inhibitors to mitigate the increased intracellular sodium concentration seen…”
BackgroundVolpe, S., Vozza, A., Lisco, G., Fanelli, M., Racaniello, D., Bergamasco, A., Triggiani, D., Pierangeli, G., Pergola, G. D., Tortorella, C., et al. (2024) · Nutrients · doi:10.3390/nu16223841 · Cited by 27
“…had already demonstrated this increase in hematocrit during the administration of SGLT2is [44–46] and associated it with a CV risk attenuation [47], a beneficial effect on renal disease [4], including the prevention of anemia in patients with impaired renal function [48], and on new-onset…”
Yeong, T. J. J., Mai, A. S., Lim, O. Z.-H., Ng, C. H., Chin, Y. H., Tay, P. W. L., Lin, C., Muthiah, M. D., Khoo, C. M., Dalakoti, M., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13822 · Cited by 25
Hasebe, M., Yoshiji, S., Keidai, Y., Minamino, H., Murakami, T., Tanaka, D., Fujita, Y., Harada, N., Hamasaki, A., & Inagaki, N. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01773-z · Cited by 27
“A meta-analysis performed with individual participant data could illustrate the independent effect of potential mediators of HF risk reduction, such as plasma volume, vascular resistance, and ketone bodies [59, 60, 64, 69].”
MethodSanz, R. L., Inserra, F., Menéndez, S. G., Mazzei, L. J., Ferder, L., & Manucha, W. A. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01240-w · Cited by 26
Sridhar, V. S., Rahman, H. U., & Cherney, D. Z. I. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13965 · Cited by 24
“Analysis of eGFR changes in CVOTs and CREDENCE suggest that between 9 and 18 months of follow up is required to be able to detect a separation in eGFR levels in favour of SGLT2 inhibitor therapy.(47) Due to the longer observation periods required to accurately evaluate trends in eGFR change over time, observational da…”
BackgroundInfluentialPotential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits
Verma, S. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.007 · Cited by 25
“23 IMPROVEMENT IN VENTRICULAR LOADING 24,25,27 − 36 Heart failure is characterized by fluid accumulation, leading to pulmonary and peripheral edema.”
Böhm, M., Fitchett, D., Ofstad, A. P., Brueckmann, M., Kaspers, S., George, J. T., Zwiener, I., Zinman, B., Wanner, C., Marx, N., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002492 · Cited by 25
“com death whereas the mediating effects from BP reductions were insignificant [33].”
BackgroundSelf-citationGenetic Variation in Sodium‐glucose Cotransporter 2 and Heart Failure
Katzmann, J. L., Mason, A. M., März, W., Kleber, M. E., Niessner, A., Blüher, M., Speer, T., & Laufs, U. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2153 · Cited by 25
“Mediation and sensitivity analyses Mediation analyses were conducted in analogy to a mediation analysis of the EMPA-REG OUTCOME trial.(15) To be considered a mediator of a treatment effect, a variable must be affected by the treatment over time (using inheritance of the selected genetic variants as a proxy), and the c…”
BackgroundMethodInfluentialAhmad, Y., Madhavan, M. V., Stone, G. W., Francis, D. P., Makkar, R., Bhatt, D. L., & Howard, J. P. (2021) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcab072 · Cited by 25
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Brito, D. A., Bettencourt, P., Carvalho, D. M., Ferreira, J., Fontes‐Carvalho, R., Franco, F., Moura, B., Silva‐Cardoso, J., de Melo, R. T., & Fonseca, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06973-3 · Cited by 27
Åkerblom, A., Oldgren, J., Latva‐Rasku, A., Johansson, L., Lisovskaja, V., Karlsson, C., Oscarsson, J., & Nuutila, P. (2019) · Upsala Journal of Medical Sciences · doi:10.1080/03009734.2018.1515281 · Cited by 25
“Increased hematocrit and an increase in plasma levels of ketones have been suggested to improve oxygenation and mitochondrial energy metabolism of the myocardium, respectively (8,14,21,24).”
BackgroundGiorgino, F., Vora, J. P., Fenici, P., & Solini, A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14055 · Cited by 24
“However, only since the publication of the EMPA-REG OUTCOME trial with the sodium-glucose cotransporter-2 (SGLT2) inhibitor, empagliflozin, has this possibility become more widely accepted.(11,12) SGLT2 inhibitors act by blocking renal SGLT2, thereby facilitating glucose excretion in urine (glycosuria) and thus reduci…”
BackgroundPellicori, P., Ofstad, A. P., FITCHETT, D. H., Zeller, C., Wanner, C., George, J. T., Zinman, B., Brueckmann, M., & Lindenfeld, J. M. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12891 · Cited by 24
“were the most important mediators of the reduction in the risk of CV death.(9) Therefore, reduction in cardiac preload and afterload, caused by an osmotic diuresis, may be one of the key mechanisms underlying the rapid reduction in SBP, body weight, and subsequent risk of HF outcomes.”
BackgroundSelf-citationAvogaro, A., de Kreutzenberg, S. V., Morieri, M. L., Fadini, G. P., & Prato, S. D. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00247-9 · Cited by 23
Zhao, Z., Wang, Y., Jiang, C., Yang, Z., Zhang, J., Lai, Y., Wang, J., Li, S., Peng, X., Li, M., et al. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.08.034 · Cited by 24
Targets for blood glucose: What have the trials told us
Valensi, P. E., Prévost, G., Schnell, O., Standl, E., & Ceriello, A. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319885456 · Cited by 27
“An exploratory mediation analysis performed from the EMPA-REG OUTCOME trial showed a modest mediation effect of glucose lowering on cardiovascular deaths.(53) If GLP1-RA and SGLT2i afford an interesting benefit for cardiovascular prevention and are associated with a low risk of hypoglycaemia, their effect on glucose l…”
MethodTanaka, M., Yamakage, H., Inoue, T., Odori, S., Kusakabe, T., Shimatsu, A., & Satoh‐Asahara, N. (2020) · Internal Medicine · doi:10.2169/internalmedicine.3473-19 · Cited by 24
“The reduction in the UA levels was also observed concurrently with the improvement in the glucose metabolism following SGLT2 inhibitor administration (28-32).”
BackgroundCardioprotective diabetes drugs: what cardiologists need to know
Brown, J. M., & Everett, B. M. (2019) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000181 · Cited by 29
Reddy, Y. N. V., Obokata, M., Jones, A. D., Lewis, G. D., Shah, S. J., Abou-Ezzedine, O. F., Fudim, M., Alhanti, B., Stevenson, L. W., Redfield, M. M., et al. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.08.008 · Cited by 23
Verma, S., Leiter, L. A., Zinman, B., Sharma, A., Mattheus, M., FITCHETT, D. H., George, J. T., Ofstad, A. P., Kosiborod, M., Wanner, C., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13374 · Cited by 24
“analyses from EMPA-REG OUTCOME suggested that the strongest mediator of the reduction in CV death was the rise in haematocrit (and haemoglobin), potentially reflecting haemoconcentration.(7) While a reduction in plasma volume (leading to improved left ventricular [LV] filling pressures”
MethodSelf-citationSGLT2 inhibitors in heart failure with reduced ejection fraction
Das, U. S., Paul, A., & Banerjee, S. (2021) · The Egyptian Heart Journal · doi:10.1186/s43044-021-00218-w · Cited by 22
McLarnon, S. R., Patel, B., Irsik, D. L., Sun, J., Ocasio, H., Crislip, G. R., Jin, C., Chen, J., Baban, B., Polichnowski, A. J., et al. (2018) · Clinical Science · doi:10.1042/cs20171630 · Cited by 22
Wang, A., Yang, K., Wang, T., Zhang, N., Tang, H., & Feng, X. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3174 · Cited by 22
“The increase in haematocrit would enhance the delivery of oxygen to tissues, which may partly explain the cardiovascular benefit of SGLT2 inhibitors.(37) Conversely, haematocrit is considered as a risk factor for VTE.”
Background
Metadata
- Authors
- Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., Hantel, S., Bluhmki, E., & Lachin, J. M.
- Affiliations
- Yale University (US)
- Mount Sinai Hospital (CA)
- St. Michael's Hospital (CA)
- Universitätsklinikum Würzburg (DE)
- Istituto di Fisiologia Clinica (IT)
- University of Freiburg (DE)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (Germany) (DE)
- George Washington University (US)
- Corresponding author
- Inzucchi, Silvio E.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-04
- Volume
- 41
- Issue
- 2
- Pages
- 356-363
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2772204795
- Cited by
- 740
- References
- 33
- Citations by year
- 2026: 33 · 2025: 48 · 2024: 71 · 2023: 83 · 2022: 103 · 2021: 109 · 2020: 139 · 2019: 96 · 2018: 56
- FWCI
- 62.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Eisai
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- empagliflozin, cardiovascular mortality, mediation analysis, type 2 diabetes, EMPA-REG OUTCOME trial, hematocrit, hemoglobin, plasma volume, uric acid, fasting blood glucose, HbA1c, urine albumin-creatinine ratio, SGLT2 inhibitors
- MeSH terms
- Adult, Aged, Benzhydryl Compounds, Blood Glucose, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Dose-Response Relationship, Drug, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Placebos, Risk Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.